The treatment and prognosis of malignant tumors are closely related to the time when the tumors are diagnosed;the earlier the diagnosis of the tumor,the better the prognosis.However,most tumors are not detected in the...The treatment and prognosis of malignant tumors are closely related to the time when the tumors are diagnosed;the earlier the diagnosis of the tumor,the better the prognosis.However,most tumors are not detected in the early stages of screening and diagnosis.It is of great clinical significance to study the correlation between multiple pathogeneses of tumors and explore simple,safe,specific,and sensitive molecular indicators for early screening,diagnosis,and prognosis.The Septin 9(SEPT9)gene has been found to be associated with a variety of human diseases,and it plays a role in the development of tumors.SEPT9 is a member of the conserved family of cytoskeletal GTPase,which consists of a P-loop-based GTP-binding domain flanked by a variable N-terminal region and a C-terminal region.SEPT9 is involved in many biological processes such as cytokinesis,polarization,vesicle trafficking,membrane reconstruction,deoxyribonucleic acid repair,cell migration,and apoptosis.Several studies have shown that SEPT9 may serve as a marker for early screening,diagnosis,and prognosis of some malignant tumors,and have the potential to become a new target for anti-cancer therapy.This article reviews the progress in research on the SEPT9 gene in early screening,diagnosis,and prognosis of tumors.展开更多
BACKGROUND The methylated septin 9(mSEPT9) assay was the first blood-based test approved by the United States Food and Drug Administration as a colorectal screening test.However, the diagnostic and prognostic role of ...BACKGROUND The methylated septin 9(mSEPT9) assay was the first blood-based test approved by the United States Food and Drug Administration as a colorectal screening test.However, the diagnostic and prognostic role of preoperative mSEPT9 for colorectal cancer(CRC) in Chinese patients is still unknown.AIM To improve the understanding of diagnostic and prognostic factors, serum m SEPT9 was detected in Chinese CRC patients.METHODS A retrospective analysis of 354 cases, of which 300 had CRC and 54 were normal,was performed in China. Patients' characteristics, treatments, and laboratory data, including age, the date of surgery, Union for International Cancer Control(UICC) stages, distant metastasis(M), and so on, were collected. Methylation levels of SEPT9 were quantified by quantitative, methylation-specific polymerase chain reaction before surgery. In addition, the effects of mSEPT9 on the occurrence and prognosis of 330 CRC cases from The Cancer Genome Atlas(TCGA) database were evaluated using bioinformatics analyses. Potential prognostic factors for overall survival(OS) and progression-free survival(PFS)were evaluated by Kaplan-Meier univariate analysis.RESULTSIn Chinese CRC patients, positive mSEPT9 was strongly associated with advanced UICC stages, deeper invasion by the primary tumor, and more distant metastasis. Methylation levels of SEPT9 were stage-dependent and showed a stepwise increase in UICC stages(I–IV), primary tumor categories(T1–T4),regional node categories(N0–N2), and distant metastasis categories(M0–M1).The patients with positive mSEPT9 showed a tendency toward lower PFS. After analyzing TCGA clinical data, the high mSEPT9 group was found to be obviously correlated only with more distant metastasis. The patients with high mSEPT9 levels showed a tendency toward lower OS. Besides, nine meaningful mSEPT9 sites were found to provide guidance for the follow-up studies.CONCLUSION MSEPT9 analysis may add valuable information to current tumor staging. Serum m SEPT9 in Chinese CRC patients appears to offer promising novel prognostic markers and might be considered for monitoring CRC recurrence.展开更多
目的探讨外周血Septin9基因甲基化(mSEPT9)检测在结直肠腺瘤诊断中的预测意义。方法收集2020年10月至2022年5月在昆明市第一人民医院病理科诊断为结直肠腺瘤的31名患者作为实验组,21例肠镜阴性受试者(消化科门诊患者)作为对照组。对2组...目的探讨外周血Septin9基因甲基化(mSEPT9)检测在结直肠腺瘤诊断中的预测意义。方法收集2020年10月至2022年5月在昆明市第一人民医院病理科诊断为结直肠腺瘤的31名患者作为实验组,21例肠镜阴性受试者(消化科门诊患者)作为对照组。对2组人员进行外周血mSEPT9检测,并收集其相应外周血CEA检测结果,对检测结果采用受试者特征曲线进行统计分析。结果mSEPT9检测对腺瘤的曲线下预测面积(AREA of the ROC:AUC)为0.7205(P<0.05),分界值(CT值)为39.55,此时对应的敏感度为90.91%,特异度为56.67%;CEA检测对腺瘤的AUC为0.5333(P>0.05)。结论外周血mSEPT9检测筛查结直肠腺瘤效果优于外周血CEA肿瘤标记物,具有较好的敏感度及特异度,一定程度上对mSEPT9筛查阳性人群再行侵入性肠镜检查,更易为该类人群接受且可早期筛查结直肠腺瘤。展开更多
文摘The treatment and prognosis of malignant tumors are closely related to the time when the tumors are diagnosed;the earlier the diagnosis of the tumor,the better the prognosis.However,most tumors are not detected in the early stages of screening and diagnosis.It is of great clinical significance to study the correlation between multiple pathogeneses of tumors and explore simple,safe,specific,and sensitive molecular indicators for early screening,diagnosis,and prognosis.The Septin 9(SEPT9)gene has been found to be associated with a variety of human diseases,and it plays a role in the development of tumors.SEPT9 is a member of the conserved family of cytoskeletal GTPase,which consists of a P-loop-based GTP-binding domain flanked by a variable N-terminal region and a C-terminal region.SEPT9 is involved in many biological processes such as cytokinesis,polarization,vesicle trafficking,membrane reconstruction,deoxyribonucleic acid repair,cell migration,and apoptosis.Several studies have shown that SEPT9 may serve as a marker for early screening,diagnosis,and prognosis of some malignant tumors,and have the potential to become a new target for anti-cancer therapy.This article reviews the progress in research on the SEPT9 gene in early screening,diagnosis,and prognosis of tumors.
基金Supported by the National Natural Science Foundation of China,No.81803035,No.81703036,and No.81572946the China Postdoctoral Science Foundation,No.2017M610510the Youth Fund of Xiangya Hospital,No.2017Q17
文摘BACKGROUND The methylated septin 9(mSEPT9) assay was the first blood-based test approved by the United States Food and Drug Administration as a colorectal screening test.However, the diagnostic and prognostic role of preoperative mSEPT9 for colorectal cancer(CRC) in Chinese patients is still unknown.AIM To improve the understanding of diagnostic and prognostic factors, serum m SEPT9 was detected in Chinese CRC patients.METHODS A retrospective analysis of 354 cases, of which 300 had CRC and 54 were normal,was performed in China. Patients' characteristics, treatments, and laboratory data, including age, the date of surgery, Union for International Cancer Control(UICC) stages, distant metastasis(M), and so on, were collected. Methylation levels of SEPT9 were quantified by quantitative, methylation-specific polymerase chain reaction before surgery. In addition, the effects of mSEPT9 on the occurrence and prognosis of 330 CRC cases from The Cancer Genome Atlas(TCGA) database were evaluated using bioinformatics analyses. Potential prognostic factors for overall survival(OS) and progression-free survival(PFS)were evaluated by Kaplan-Meier univariate analysis.RESULTSIn Chinese CRC patients, positive mSEPT9 was strongly associated with advanced UICC stages, deeper invasion by the primary tumor, and more distant metastasis. Methylation levels of SEPT9 were stage-dependent and showed a stepwise increase in UICC stages(I–IV), primary tumor categories(T1–T4),regional node categories(N0–N2), and distant metastasis categories(M0–M1).The patients with positive mSEPT9 showed a tendency toward lower PFS. After analyzing TCGA clinical data, the high mSEPT9 group was found to be obviously correlated only with more distant metastasis. The patients with high mSEPT9 levels showed a tendency toward lower OS. Besides, nine meaningful mSEPT9 sites were found to provide guidance for the follow-up studies.CONCLUSION MSEPT9 analysis may add valuable information to current tumor staging. Serum m SEPT9 in Chinese CRC patients appears to offer promising novel prognostic markers and might be considered for monitoring CRC recurrence.
文摘目的探讨外周血Septin9基因甲基化(mSEPT9)检测在结直肠腺瘤诊断中的预测意义。方法收集2020年10月至2022年5月在昆明市第一人民医院病理科诊断为结直肠腺瘤的31名患者作为实验组,21例肠镜阴性受试者(消化科门诊患者)作为对照组。对2组人员进行外周血mSEPT9检测,并收集其相应外周血CEA检测结果,对检测结果采用受试者特征曲线进行统计分析。结果mSEPT9检测对腺瘤的曲线下预测面积(AREA of the ROC:AUC)为0.7205(P<0.05),分界值(CT值)为39.55,此时对应的敏感度为90.91%,特异度为56.67%;CEA检测对腺瘤的AUC为0.5333(P>0.05)。结论外周血mSEPT9检测筛查结直肠腺瘤效果优于外周血CEA肿瘤标记物,具有较好的敏感度及特异度,一定程度上对mSEPT9筛查阳性人群再行侵入性肠镜检查,更易为该类人群接受且可早期筛查结直肠腺瘤。
